Activity of retapamulin (SB-275833), a novel pleuromutilin, against selected resistant gram-positive cocci |
| |
| Authors: | Jones Ronald N Fritsche Thomas R Sader Helio S Ross James E |
| |
| Institution: | JMI Laboratories, Inc., North Liberty, IA 52317, USA. |
| |
| Abstract: | Retapamulin (SB-275833), the first pleuromutilin to be developed for human topical use, was tested against a selected population of staphylococci and beta-hemolytic streptococci. The MIC90 results for retapamulin were 0.12 microg/ml for Staphylococcus aureus and < or = 0.03 microg/ml for Streptococcus pyogenes; no cross-resistance was observed for organism subsets resistant to oxacillin, erythromycin, or mupirocin. |
| |
| Keywords: | |
| 本文献已被 PubMed 等数据库收录！ |
|
